FDA Greenlights Drugs to Battle Screwworms in Cats and Dogs
Published Date: 12/29/2025
Notice
Summary
The FDA just gave the green light for two new emergency animal drugs to treat nasty New World screwworm infections in dogs, puppies, cats, and kittens. These quick-acting treatments are now officially authorized as of late 2025 to help protect pets from this serious health threat. Pet owners and vets can expect faster access to these lifesaving drugs without extra costs right now.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
EUA for Dog Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio (lotilaner) to treat New World screwworm (NWS) infestations in dogs and puppies. This authorization is effective October 24, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
EUA for Cat Screwworm Treatment
The FDA issued an Emergency Use Authorization (EUA) to Elanco US Inc. for Credelio CAT (lotaliner) to treat New World screwworm (NWS) infestations in cats and kittens. This authorization is effective November 21, 2025 and allows emergency use and introduction into interstate commerce under the FD&C Act section 564.
Faster Access to Pet Treatments Now
The notice states that pet owners and veterinarians can expect faster access to these lifesaving drugs for New World screwworm and that this access is available without extra costs right now. The two EUAs became effective October 24, 2025 and November 21, 2025, respectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-23913 — Carbon and Certain Alloy Steel Wire Rod From China; Determinations
The U.S. government decided to keep special taxes on carbon and certain alloy steel wire rod imported from China because removing them could hurt American steel makers. These taxes help protect U.S. jobs and businesses from unfair competition. This decision was finalized at the end of 2025 and means importers will keep paying these extra fees for now.
Next: 2025-23952 — Sunshine Act Meetings
The National Council on Disability is holding a two-day meeting in January 2026, both in Orlando and online, to discuss important issues like youth in nursing homes, disaster experiences, and accessible transportation. This meeting affects people with disabilities, especially in Florida, and aims to improve policies and services. No new costs are mentioned, but the event invites public input and shares updates on ongoing projects.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in